Zhengye Biotechnology Holding (ZYBT) Common Equity (2023 - 2024)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Zhengye Biotechnology Holding (ZYBT) has disclosed Common Equity for 2 consecutive years, with $39.5 million as the latest value for Q4 2024.

• Quarterly Common Equity rose 4.32% to $39.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $39.5 million through Dec 2024, up 4.32% year-over-year, with the annual reading at $48.3 million for FY2024, 25.1% up from the prior year.
• Common Equity for Q4 2024 was $39.5 million at Zhengye Biotechnology Holding, up from $37.9 million in the prior quarter.
• The five-year high for Common Equity was $39.5 million in Q4 2024, with the low at $37.9 million in Q4 2023.

Peer Comparison